FemasysFEMY -1.91%55 EBITDA Margin % is 287.76% as of Mar. 2026. GuruFocus rates FEMY with a GF Score™ of 55/100 and a GF Value™ of $12.23 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Femasys ranks worse than 91.05% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Femasys's EBITDA for the
three
months ended in Mar. 2026 was $1.22 Mil. Femasys's Revenue for the
three
months ended in Mar. 2026 was $0.43 Mil. Therefore, Femasys's EBITDA margin for the quarter that ended in Mar. 2026 was 287.76%.
Femasys (NAS:FEMY) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Femasys EBITDA Margin % Related Terms
Femasys EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Femasys's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FEMY vs RVP, HBIO, ZJYL: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Femasys's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Femasys EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Femasys's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Femasys's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Femasys (FEMY) has a EBITDA Margin % of 287.76% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Femasys and its competitors. According to the industry distribution chart, Femasys ranks #743 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 91.1%.
Is Femasys' EBITDA Margin % too high?
Femasys' current EBITDA Margin % is 287.76%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Femasys' value of 287.76% is 3749.6% above this industry median. Based on the distribution chart, Femasys ranks #743 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Femasys has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Femasys' EBITDA Margin % compare to RVP and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Femasys ranks #743 out of 816 companies for EBITDA Margin %. This places Femasys in the lower half of its industry. The industry median EBITDA Margin % is 7.48. Femasys' value of 287.76% is 3749.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Femasys's current EBITDA Margin % of 287.76% is 3749.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Femasys and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Femasys's current EBITDA Margin % is 287.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Femasys stock overvalued right now?
Based on GuruFocus' analysis, Femasys (FEMY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.23, compared to a current price of $3.60 — trading 70.6% below its estimated fair value. The current EBITDA Margin % is 287.76% and 3749.6% above the Medical Devices & Instruments industry median of 7.48. Femasys' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Femasys (FEMY), the current EBITDA Margin % is 287.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Femasys (FEMY) Overvalued in 2026?
Based on GuruFocus' analysis, Femasys stock appears to be undervalued.
The current stock price of $3.60 is trading 70.6% below its estimated GF Value™ of $12.23.
GuruFocus considers Femasys to be Possible Value Trap.
Key valuation signals for FEMY:
EBITDA Margin %: 287.76%
GF Value™: $12.23 vs. price of $3.60 (70.6% below fair value)
Industry Position: 3749.6% above the Medical Devices & Instruments median (#743 of 816)
No single metric tells the full story. See the FEMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
55GF Score
Get the complete analysis for FEMY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FEMY has been successfully added to your 
